Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits
Cancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has been associated with rejection rates up to 40%, in retrospective studies. The main challenge is to...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2024-11-01
|
| Colección: | Transplant International |
| Materias: | |
| Acceso en línea: | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13204/full |